Insights

Strategic Expansion AGC Biologics is rapidly expanding its US, European, and Japanese manufacturing footprint with new collaborations and site developments, creating opportunities to offer end-to-end CDMO services across development, scale-up, and GMP manufacturing for clients seeking global CMO capacity.

MultiModal Capabilities The company provides development and manufacturing for mammalian and microbial proteins, pDNA, mRNA, viral vectors, and engineered cell therapies, suggesting upsell potential to clients needing integrated solutions across multiple modalities and pipeline stages.

Site Utilization High-profile multi-year contracts and secured capacity at Yokohama indicate strong demand and readiness to allocate substantial capacity; sales efforts can target large biopharma players seeking reliable long-term manufacturing partners with international presence.

Collaborative Growth Recent partnerships with Asimov and Pyramid Pharma, plus Proliferation of collaborations for microbial and fill-finish capabilities, point to opportunities to position AGC Biologics as a preferred partner for integrated supply chain solutions and technology-enabled manufacturing.

Clinical to Commercial Active transitions from clinical development to GMP manufacturing and process development in multiple regions highlight opportunities to engage biotech firms early in development for ongoing scale-up, fill-finish, and commercial manufacturing programs.

Similar companies to AGC Biologics

AGC Biologics Tech Stack

AGC Biologics uses 8 technology products and services including HubSpot Analytics, Microsoft Power Automate, Power BI, and more. Explore AGC Biologics's tech stack below.

Media & News

AGC Biologics's Email Address Formats

AGC Biologics uses at least 4 email formats:
AGC Biologics Email FormatsExamplePercentage
FLast@agcbio.comJDoe@agcbio.com
92%
First.Last@agcbio.comJohn.Doe@agcbio.com
4%
LF@agcbio.comDJ@agcbio.com
3%
FL@agcbio.comJD@agcbio.com
1%

Frequently Asked Questions

What is AGC Biologics's official website and social media links?

Minus sign iconPlus sign icon
AGC Biologics's official website is agcbio.com and has social profiles on LinkedIn.

How much revenue does AGC Biologics generate?

Minus sign iconPlus sign icon
As of October 2026, AGC Biologics's annual revenue is estimated to be $500M - $1B.

What is AGC Biologics's NAICS code?

Minus sign iconPlus sign icon
AGC Biologics's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does AGC Biologics have currently?

Minus sign iconPlus sign icon
As of October 2026, AGC Biologics has approximately 2.5K employees across 6 continents, including Europe, North America and Asia. Key team members include Chief Executive Officer & President: A. S., Chief Business Officer: C. W. and Chief Technical Officer: K. M. Explore AGC Biologics's employee directory with LeadIQ.

What industry does AGC Biologics belong to?

Minus sign iconPlus sign icon
AGC Biologics operates in the Pharmaceutical Manufacturing industry.

What technology does AGC Biologics use?

Minus sign iconPlus sign icon
AGC Biologics's tech stack includes HubSpot Analytics, Microsoft Power Automate, Power BI, SAS, AutoCAD, Asana, Cisco and VMware.

What is AGC Biologics's email format?

Minus sign iconPlus sign icon
AGC Biologics's email format typically follows the pattern of FLast@agcbio.com. Find more AGC Biologics email formats with LeadIQ.
AGC Biologics logo

AGC Biologics

Pharmaceutical ManufacturingWashington, United States1001-5000 Employees

AGC Biologics is a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) in the pharmaceutical manufacturing industry, based in Bothell, Washington, with a workforce of about 1,000 to 5,000 employees. The company provides development and manufacturing services for mammalian and microbial-based therapeutic proteins, as well as plasmid DNA, mRNA, viral vectors, and genetically engineered cell therapies. Its global network includes cGMP-compliant facilities in Seattle, Washington; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and in Chiba and Yokohama, Japan. In 2026, AGC Biologics expanded its presence in Japan with a new Yokohama facility and an expansion in Chiba to support process development and GMP manufacturing for clinical trials, and it signed a microbial CDMO contract with Teikoku Seiyaku Co., Ltd. The company has received industry recognition for regulatory and quality leadership, client service, and manufacturing performance.

Section iconCompany Overview

Website
agcbio.com
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Employees
1001-5000

Section iconFunding & Financials

  • $500M - $1B

    AGC Biologics's revenue is estimated to be in the range of $500M - $1B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.